Clinical trial
A Randomized, Controlled, Open-label Study of the Safety and Efficacy of Ferrlecit® vs Oral Iron in Iron Deficient Patients With Chronic Kidney Disease Being Treated With Erythropoietic Therapy
NCT00224042 is registered in ClinicalTrials.gov with Watson Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Controlled, Open-label Study of the Safety and Efficacy of Ferrlecit® vs Oral Iron in Iron Deficient Patients With Chronic Kidney Disease Being Treated With Erythropoietic Therapy
- Lead sponsor
- Watson Pharmaceuticals
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- April 30, 2003
- Completion date
- Not reported
- Enrollment
- 52 (actual)
- Sites
- 24
Conditions
As the registry lists them; a condition with its own page is linked.